ERBB2 and breast cancer: However, a recent genomic cohort study demonstrated that TP53 mutations are associated with a lack of long-term disease control in patients with metastatic HR+/HER2- breast cancer treated with first-line CDK4/6 inhibitors and endocrine therapy 68.